华北制药：获得腺苷钴胺胶囊药品注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Adenosylcobalamin capsules (0.5mg), indicating a significant advancement in its product pipeline for blood and hematopoietic system medications [1] Group 1: Product Approval - The company has obtained the Drug Registration Certificate for Adenosylcobalamin capsules (0.5mg) [1] - Adenosylcobalamin is primarily used for the prevention and treatment of Vitamin B12 deficiency, particularly in cases of inadequate dietary intake due to various conditions such as consumptive diseases, hyperthyroidism, pregnancy, and lactation [1] - The approval confirms that the product meets the basic entry requirements for centralized procurement bidding and that its efficacy is equivalent to that of the original research product [1]